Loading...

Jyoti Mayadev

TitleAssociate Clinical Professor -
InstitutionUniversity of California San Diego
DepartmentRadiation Medicine and Applied Science
Address9500 Gilman Drive #0843
La Jolla CA 92093
Phone858-246-2051
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Mayadev J, Klapheke A, Yashar C, Hsu IC, Kamrava M, Mundt AJ, Mell LK, Einck J, Benedict S, Valicenti R, Cress R. Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California. Gynecol Oncol. 2018 Apr 27. PMID: 29709291.
      View in: PubMed
    2. Mayadev J, Lim J, Durbin-Johnson B, Valicenti R, Alvarez E. Smoking Decreases Survival in Locally Advanced Cervical Cancer Treated With Radiation. Am J Clin Oncol. 2018 Mar; 41(3):295-301. PMID: 26808259.
      View in: PubMed
    3. Mayadev J, Li CS, Lim J, Valicenti R, Alvarez EA. Alcohol Abuse Decreases Pelvic Control and Survival in Cervical Cancer: An Opportunity of Lifestyle Intervention for Outcome Improvement. Am J Clin Oncol. 2017 Oct; 40(5):451-457. PMID: 25784565.
      View in: PubMed
    4. Mayadev J, Viswanathan A, Liu Y, Li CS, Albuquerque K, Damato AL, Beriwal S, Erickson B. American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer. Brachytherapy. 2017 Jan - Feb; 16(1):22-43. PMID: 28109631.
      View in: PubMed
    5. Michaud AL, Benedict S, Montemayor E, Hunt JP, Wright C, Mathai M, Mayadev J. Workflow efficiency for the treatment planning process in CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy. 2016 Sep-Oct; 15(5):578-83. PMID: 27476646.
      View in: PubMed
    6. Tait LM, Hoffman D, Benedict S, Valicenti R, Mayadev J. The use of MRI deformable image registration for CT-based brachytherapy in locally advanced cervical cancer. Brachytherapy. 2016 May-Jun; 15(3):333-40. PMID: 26882845.
      View in: PubMed
    7. Rash D, Hess C, Lentz S, Tait L, Michaud A, Mayadev J. Prospective evaluation of patient satisfaction after the use of brachytherapy specific educational materials for cervical cancer. Brachytherapy. 2016 Jan-Feb; 15(1):65-70. PMID: 26521660.
      View in: PubMed
    8. Rash D, Durbin-Johnson B, Lim J, Dieterich S, Huddleston A, Yi S, Mayadev J. Dose delivered to the lumbosacral plexus from high-dose-rate brachytherapy for cervical cancer. Int J Gynecol Cancer. 2015 Jun; 25(5):897-902. PMID: 25768077; PMCID: PMC4563992.
    9. Hess C, Lee A, Fish K, Daly M, Cress RD, Mayadev J. Socioeconomic and racial disparities in the selection of chest wall boost radiation therapy in californian women after mastectomy. Clin Breast Cancer. 2015 Jun; 15(3):212-8. PMID: 25499694; PMCID: PMC4484791.
    10. Mayadev J, Einck J, Elson S, Rugo H, Hwang S, Bold R, Daroui P, McCloskey S, Yashar C, Kim D, Fowble B. Practice patterns in the delivery of radiation therapy after mastectomy among the University of California Athena Breast Health Network. Clin Breast Cancer. 2015 Feb; 15(1):43-7. PMID: 25245425.
      View in: PubMed
    11. Mayadev J, Fish K, Valicenti R, West D, Chen A, Martinez S, Phillips T. Utilization and impact of a postmastectomy radiation boost for invasive breast cancer. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e269-78. PMID: 25407878.
      View in: PubMed
    12. Mayadev J, Qi L, Lentz S, Benedict S, Courquin J, Dieterich S, Mathai M, Stern R, Valicenti R. Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy. 2014 May-Jun; 13(3):233-9. PMID: 24559793.
      View in: PubMed
    13. Rash DL, Lee YC, Kashefi A, Durbin-Johnson B, Mathai M, Valicenti R, Mayadev J. Clinical response of pelvic and para-aortic lymphadenopathy to a radiation boost in the definitive management of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2013 Oct 01; 87(2):317-22. PMID: 23906933.
      View in: PubMed
    14. Lee YC, Rash DL, Stern RL, Mayadev J. The equivalent dose contribution from high-dose-rate brachytherapy to positive pelvic lymph nodes in locally advanced cervical cancer. Brachytherapy. 2013 Nov-Dec; 12(6):555-9. PMID: 23880417.
      View in: PubMed
    15. Lim J, Durbin-Johnson B, Valicenti R, Mathai M, Stern RL, Mayadev J. The impact of maximum rectal distention and tandem angle on rectal dose delivered in 3D planned gynecologic high dose-rate brachytherapy. Int J Gynecol Cancer. 2013 Jul; 23(6):1078-83. PMID: 23792603; PMCID: PMC3706279.
    16. Lim J, Durbin-Johnson B, Valicenti R, Mathai M, Stern RL, Mayadev J. The impact of body mass index on rectal dose in locally advanced cervical cancer treated with high-dose-rate brachytherapy. Brachytherapy. 2013 Nov-Dec; 12(6):550-4. PMID: 23706512.
      View in: PubMed
    17. Rash D, Hagar Y, Cui J, Hunt JP, Valicenti R, Mayadev J. Interfraction motion of the vaginal apex during postoperative intensity modulated radiation therapy: are we missing the target? Int J Gynecol Cancer. 2013 Feb; 23(2):385-92. PMID: 23287959.
      View in: PubMed
    18. Fowble BL, Einck JP, Kim DN, McCloskey S, Mayadev J, Yashar C, Chen SL, Hwang ES. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):494-503. PMID: 22579377.
      View in: PubMed
    19. Greene DE, Mayadev J, Valicenti RK. Radiation treatment for patients with intermediate-risk prostate cancer. Ther Adv Urol. 2012 Jun; 4(3):113-24. PMID: 22654963; PMCID: PMC3361750.
    20. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012 Feb; 109 Suppl 1:22-9. PMID: 22239226.
      View in: PubMed